IQVIA (NYSE:IQV) Now Covered by Analysts at Royal Bank Of Canada

Royal Bank Of Canada started coverage on shares of IQVIA (NYSE:IQV) in a report released on Tuesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $221.00 price target on the medical research company’s stock.

Several other equities analysts have also recently commented on the stock. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Mizuho set a $215.00 price target on shares of IQVIA in a research report on Monday, February 23rd. Stifel Nicolaus lowered their price objective on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Barclays reduced their target price on IQVIA from $230.00 to $210.00 and set an “equal weight” rating for the company in a research report on Friday, February 6th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $231.13.

IQVIA Price Performance

Shares of NYSE IQV opened at $174.14 on Tuesday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The stock has a market cap of $29.55 billion, a PE ratio of 22.16, a price-to-earnings-growth ratio of 1.68 and a beta of 1.39. The stock has a fifty day moving average of $210.17 and a 200-day moving average of $207.90.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. During the same quarter last year, the company earned $3.12 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities research analysts anticipate that IQVIA will post 10.84 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of IQV. Vanguard Group Inc. lifted its holdings in shares of IQVIA by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after acquiring an additional 159,899 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of IQVIA by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock valued at $982,272,000 after buying an additional 24,453 shares during the last quarter. Boston Partners increased its holdings in shares of IQVIA by 14.9% in the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock worth $923,276,000 after buying an additional 530,672 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of IQVIA by 16.2% in the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock valued at $856,468,000 after acquiring an additional 528,753 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in IQVIA by 1.2% during the 3rd quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock valued at $683,323,000 after acquiring an additional 41,643 shares during the period. 89.62% of the stock is currently owned by institutional investors.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.